Every 10-Q that Senseonics (SENS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SENS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SENS filings page.
Senseonics Holdings, Inc. reported sharply higher revenue but larger losses for the six months ended June 30, 2026. Total revenue was $26,194 thousand, more than doubling from $12,906 thousand a year earlier, driven mainly by U.S. commercialization of the Eversense E3 and Eversense 365 CGM systems and the transition of European distribution back in-house.
Operating expenses increased substantially as the company built its direct sales, marketing, and support infrastructure and continued product development, resulting in an operating loss of $67,834 thousand and a net loss of $69,038 thousand, or $1.33 basic and diluted net loss per share.
Liquidity improved through equity and debt financing. As of June 30, 2026, the company held $142.7 million in unrestricted cash, cash equivalents and marketable securities. It raised approximately $86.0 million in net proceeds from a May 2026 equity and pre-funded warrant offering, received about $6.2 million via an at-the-market program, and expanded its Hercules senior secured term loan facility to up to $140.0 million, with $55.0 million drawn. Net cash used in operating activities was $62,163 thousand, and management states that available resources and expected cash flows are sufficient for at least the next twelve months.
Senseonics Holdings, Inc. reported higher sales but wider losses for the quarter ended March 31, 2026 as it internalizes commercialization of its Eversense implantable CGM systems.
Total revenue rose to $11.7 million from $6.3 million a year earlier, driven mainly by U.S. sales now representing nearly 80% of revenue. However, operating expenses increased sharply, leading to a net loss of $32.3 million, compared with a $14.3 million loss in the prior-year quarter. Cash, cash equivalents and marketable securities were $64.3 million as of March 31, 2026. Subsequent to quarter end, the company raised an estimated $86.0 million net through an underwritten equity offering and secured access to up to $140.0 million in term loans, and management concluded that prior substantial doubt about its ability to continue as a going concern has been alleviated.
Senseonics Holdings, Inc. filed its Q3 2025 10‑Q, reporting total revenue of $8.1 million, up from $4.3 million a year ago, and a net loss of $19.5 million. Gross profit was $3.5 million versus a gross loss in the prior year period.
The company ended the quarter with $111.0 million in unrestricted cash, cash equivalents and marketable securities. Management disclosed that substantial doubt exists regarding its ability to continue as a going concern, citing expected cash needs and covenant requirements under its amended loan agreement.
Senseonics amended its term loan facility on September 3, 2025, increasing capacity to $100.0 million (maturing September 3, 2029) with a minimum cash covenant. It also raised capital via a $57.5 million public offering and a concurrent $20.3 million private placement with Abbott in May, and established a $100.0 million at‑the‑market program in August. A 1‑for‑20 reverse stock split became effective on October 17, 2025. The company signed an MOU with Ascensia to transition Eversense commercialization back to Senseonics beginning January 1, 2026.